Commentary|Videos|November 20, 2026

Why Early Therapy Matters in Resistant Gram-Negative Lung Infections

Fact checked by: Maggie L. Shaw

Sean Nguyen, PharmD, discusses PROVE data on cefiderocol for resistant respiratory infections and why early, appropriate therapy matters in the ICU.

Captions are auto-generated.

The median time from index culture to treatment with cefiderocol (Fetroja; Shionogi) was 4 days for US patients with respiratory tract infections (RTIs), most of which were caused by carbapenem-resistant Gram-negative bacteria (CR-GNB), according to a recent study.1

These data, presented at IDWeek in Washington, DC, from October 21-24, 2026, come from a US subgroup analysis of PROVE, an international, observational medical chart review study conducted from November 2020 to July 2024. Inappropriate antibiotic treatment for RTIs caused by CR-GNB, particularly infections of nosocomial origin or those complicated by sepsis or septic shock, has been associated with increased morbidity and mortality.1

The analysis included 266 hospitalized patients with RTIs who received cefiderocol for the first time for at least 72 hours. Nearly all (96.6%) had at least 1 risk factor for CR-GNB infection. Most (74.8%) were in the intensive care unit (ICU), and 66.2% were receiving mechanical ventilation when cefiderocol was started.1

Cefiderocol was beneficial for RTIs caused mainly by nonfermenting GNB, with an overall clinical cure rate of 65.4% and a clinical response rate of 76.7%. All-cause mortality at day 30 was 25.9%. Clinical cure rates were higher when cefiderocol was used for documented infections (68.6%) or empirically (73.3%) than as salvage therapy after a prior regimen had failed (43.9%), although the study used only descriptive statistics.1

Shortening the time to appropriate therapy requires actionable information that clinicians can use as early as possible, such as microbiology results and rapid diagnostics, Sean Nguyen, PharmD, senior medical director of infectious diseases at Shionogi and study coauthor, said in an interview with The American Journal of Managed Care®. That information should be used in close collaboration with the microbiology laboratory, infectious disease clinicians, and stewardship teams, he explained.

"Rapid diagnostics is also a complementary tool, and it's important for helping clinicians identify an infecting pathogen or resistance mechanism earlier," Nguyen said. "Earlier access to data, any type of data, including microbiology data, can help reduce the uncertainty that often exists with critically ill patients, where appropriate therapy started earlier can lead to better outcomes."

When considering newer antibiotics, clinicians should also weigh the total cost of care, Nguyen noted. "There's been several studies now [showing] that delayed antibiotic therapy can lead to higher mortality, longer lengths of stay, and significantly higher hospital costs," he said. "So in particular for patients with resistant Gram-negative infections, getting effective therapy as soon as possible will not only improve their outcomes, but it could potentially also reduce the economic burden."

Reference

1. Carr A, Santerre Henriksen A, Gill K, Nguyen ST. Outcomes of cefiderocol treatment in US patients with respiratory tract infections: subgroup analysis of the PROVE observational study. Presented at: IDWeek 2026; October 21-24, 2026; Washington, DC. Poster 144.


Related to this article